Interim Phase 3 findings will be presented in a prestigious late-breaking oral session at the leading meeting for kidney health professionals. – ...

Humacyte, Inc. announced that interim results from its V012 Phase 3 clinical trial have been accepted for a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 ...

DaVita announced it will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years.

This year’s SIRHCM 2026 symposium holds strategic significance in advancing a key trend in modern medicine: the use of ...

AV production simulation game you can freely film, edit, and sell your creations! Work with charming heroines to produce top-tier masterpieces, boost your reputation, and grow your sales. Striving to ...

Despite robust evidence supporting guideline-directed medical therapy (GDMT) for cardiovascular–kidney–metabolic syndrome, uptake remains low. Structural, economic and equity-related barriers must be ...

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

News zur HUMACYTE AKTIE ✓ und aktueller Realtime-Aktienkurs ✓ Humacyte, Inc: Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik ...

Humacyte, Inc. a annoncé que les résultats intermédiaires de son essai clinique de phase 3 V012 ont été retenus pour une ...

DaVita heeft aangekondigd dat het tijdens ASN Kidney Week 2026 van de American Society of Nephrology zeven onderzoeken zal ...